Loading...
Loading...
XenoPort, Inc.
XNPT announced today top-line results from its
pivotal Phase 3 clinical trial of arbaclofen placarbil (AP) for the
treatment of patients with spasticity due to multiple sclerosis (MS).
The trial was unsuccessful in demonstrating that AP provided
statistically significant improvement relative to placebo in the
co-primary endpoints of the study.
Ronald W. Barrett, Ph.D., chief executive officer of XenoPort, stated,
“We are obviously disappointed that the co-primary efficacy endpoints
were not met. Based on the results of the study, we have decided to
terminate further investment in this program. We will be working
diligently to shut down all activities related to AP development, and
plan to provide an update in the
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in